News
Now on Phase 1 trial, REC-3565 is being developed using Recursion Pharmaceuticals, Inc.’s (NASDAQ:RXRX) advanced AI platform, ...
In a recent social media post, Peter Ray, senior director of medicinal chemistry at Recursion Pharmaceuticals, Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback